Background and Motivation

I’m interested in advancing the science around the usage of immunohistochemical biomarkers in order to differentiate chromophobe renal cell carcinoma (ChRCC) from renal oncocytoma (RO). These two tumors have vastly distinct management and follow-up strategies but are currently hard to differentiate without the use of expensive and often unavailable techniques, like electron microscopy, fluorescence in situ hybridisation, proteomics or cytogenetics.

While relatively rare, ChRCC can be found in about 5% of cases of renal cell carcinoma. Compared with more aggressive and more common clear cell renal cell carcinoma and papillary cell renal cell carcinoma, ChRCC has indolent clinical behaviour. Unfortunately, however, ChRCC exhibits a malignant potential and can metastasize.

RO originates from the same type of cells as ChRCC and exhibits very similar morphological features but is, nonetheless, a benign tumor with a good prognosis.

Through researching how immunohistochemical biomarkers can help fulfill the task of effectively differentiating them, I hope to help reduce the cost of proper diagnosis and avoid unnecessary surgery. 

Third Party Research

Published Research

Histological features of Chromophobe Renal Cell Carcinoma

Journal Paper
V. V. Baranovska, A. M. Romanenko, L. M. Zakhartseva
Eastern Ukrainian Medical Journal, Vol 8 No 1 (2020), page 15
Publication year: 2020

Histological differential diagnostics of renal oncocytoma

Journal Paper
V. V. Baranovska, A. M. Romanenko, L. M. Zakhartseva
Experimental Oncology 2020, Volume 42, Issue 3, Pages 233-237
Publication year: 2020

Research Hypothesis

While there are certainly many studies where individual biomarkers were applied to differentiate between these kinds of tumors, finding one that reliably does this remains elusive. Moreover, no studies to date have looked into the effectiveness of each biomarker when conditioning to the observable properties of the tumor (e.g. their nuclear form, their shape, etc).

I plan on studying the immunohistochemical profile of a large sample of ChRCCs and ROs, after being subjected to different immunohistochemical biomarkers –– and to investigate the potential effectiveness of combining the results of more than one biomarker, as well as when slicing by specific observable properties of the tumors.

If you are interested in my research, and can contribute information and/or offer to collaborate, please reach out to me.